Assuming the COMPASS results are enough to convince regulators to make the low dose of rivaroxaban used in the study available to clinicians, the trial should influence how patients with stable ...
MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary ...
COMPASS STUDY PRESENTED AT ESC CONGRESS 2017 – LARGEST RIVAROXABAN STUDY TO DATE, ENROLLED 27,395 PATIENTS TO INVESTIGATE CAD AND PAD Bayer’s data shows Xarelto® (rivaroxaban) significantly lowers the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results